Identification of the risk factors associated with hypocalcemia induced by denosumab

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 10, 2013, Pages 1622-1626

  Okada, Naoto ^a   Kawazoe, Kazuyoshi ^a,b   Teraoka, Kazuhiko ^a   Kujime, Toshihide ^a   Abe, Masahiro ^c   Shinohara, Yasuo ^b   Minakuchi, Kazuo ^b  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Creatinine clearance; Denosumab; Hypocalcemia; Risk factor; Zoledronic acid

Indexed keywords

CALCIUM; COLECALCIFEROL; CREATININE; DENOSUMAB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BREAST CANCER; CREATININE CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; HYPOCALCEMIA; JAPAN; KIDNEY CANCER; KIDNEY FAILURE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; CREATININE; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; OSTEOCLASTS; RANK LIGAND; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84887114892     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00496     Document Type: Article

References (21)

1. Coleman RE. Skeletal complications of malignancy. Cancer, 80 (Suppl.), 1588-1594 (1997). (Pubitemid 27444031)
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 12, 6243s-6249s (2006). (Pubitemid 44703797)
3. Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes J, Goas J, Chen B, Group ZAPCS, Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst., 94, 1458-1468 (2002).
4. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Zoledronic Acid versus Placebo in the Treatment of Skeletal Metastases in Patients with Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol., 21, 3150-3157 (2003). (Pubitemid 46606297)
5. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol., 23, 3314-3321 (2005).
6. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan H, Capparelli C, Starnes C, Weimann B, Dunstan C, Kostenuik P. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology, 146, 3235-3243 (2005). (Pubitemid 41058092)
7. Roodman GD, Dougall W. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat. Rev., 34, 92-101 (2008). (Pubitemid 351181016)
8. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J. Urol., 182, 509-516, discussion, 515 (2009).
9. Stopeck AT, Lipton A, Body J, Steger G, Tonkin K, de Boer H, Lichinitser M, Fujiwara Y, Yardley D, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol., 28, 5132-5139 (2010).
10. Kurata T, Nakagawa K. Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn. J. Clin. Oncol., 42, 663-669 (2012).
11. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll P, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol., 29, 1125-1132 (2011).
12. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang HI, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377, 813-822 (2011).
13. Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D, Richardson G, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer, 48, 3082-3092 (2012).
14. Block GA, Bone H, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Miner. Res., 27, 1471-1479 (2012).
15. Pharmaceuticals and Medical Devices Agency.: , cited 19 April, 2013
16. Paller CJ, Carducci M, Philips G. Management of bone metastases in refractory prostate cancer-role of denosumab. Clin. Interv. Aging, 7, 363-372 (2012).
17. Buonerba C, Caraglia M, Malgieri S, Perri F, Bosso D, Federico P, Ferro M, Rizzo M, Palmieri G, Di Lorenzo G. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin. Biol. Ther., 13, 149-151 (2013).
18. Cockcroft DW, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41 (1976).
19. Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, de Bonis E, Darias E, González-Posada J, Losada M, Rufino M, Felsenfeld AJ, Rodríguez M. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int., 47, 1434-1442 (1995).
20. Fukumoto S. Transport of minerals in renal tubules and its hormonal regulation. Clin. Calcium, 17, 677-683 (2007).
21. Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris A, Bottini A, Dogliotti L, Angeli A, Berruti A. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br. J. Cancer, 98, 1753-1758 (2008). (Pubitemid 351748853)